#ESMO14 - Poster: Long-term cellular response and variables correlating with humoral response in STAND, a randomised phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer

MADRID, SPAIN (UroToday.com) - Presented by Drake CG,^{1, 2} Kibel AS,³ Adams G,⁴ Karsh LI,⁵ Elfiky A,³ Shore ND,⁶ Vogelzang NJ,⁷ Corman JM,⁸ Tyler RC,⁹ McCoy C,⁹ DeVries T,⁹ Sheikh N,⁹ and Antonarakis ES¹ at the European Society for Medical Oncology (ESMO) 2014 Congress - September 26 - 30, 2014 - Madrid, Spain.

¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA;
²Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA;
³Brigham and Women’s Hospital, Harvard University, Boston, MA, USA;
⁴Urology Cancer Center of Alabama, Homewood, AL, USA;
⁵The Urology Center of Colorado, Denver, CO, USA;
⁶Carolina Urologic Research Center, Myrtle Beach, SC, USA;
⁷US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA;
⁸Virginia Mason Medical Center, Seattle, WA, USA;
⁹Dendreon Corporation, Seattle, WA, USA